Spectrum Pharmaceuticals, Inc.  

(Public, NASDAQ:SPPI)   Watch this stock  
Find more results for SPPI
+0.08 (1.72%)
After Hours: 4.74 0.00 (0.00%)
Sep 27, 5:58PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.60 - 4.74
52 week 4.14 - 7.74
Open 4.66
Vol / Avg. 0.00/1.03M
Mkt cap 373.11M
P/E     -
Div/yield     -
EPS -0.85
Shares 80.22M
Beta 1.47
Inst. own 70%
Nov 2, 2016
Q3 2016 Spectrum Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 12, 2016
Spectrum Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Sep 9, 2016
Spectrum Pharmaceuticals Inc at Biocentury NewsMakers in the Biotech Industry
Aug 9, 2016
Q2 2016 Spectrum Pharmaceuticals Inc Earnings Call
Aug 9, 2016
Q2 2016 Spectrum Pharmaceuticals Inc Earnings Release
Jul 13, 2016
Spectrum Pharmaceuticals Inc at Cantor Fitzgerald Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -71.56% -31.24%
Operating margin -65.04% -25.06%
EBITD margin - -1.05%
Return on average assets -23.46% -11.17%
Return on average equity -43.89% -21.74%
Employees 212 -
CDP Score - -


11500 S Eastern Ave Ste 240
HENDERSON, NV 89052-5576
United States - Map
+1-702-8356300 (Phone)
+1-702-2607405 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin's lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

Officers and directors

Rajesh C. Shrotriya M.D. Chairman of the Board, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Joseph W. Turgeon President, Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Kurt A. Gustafson Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Gilles R. Gagnon Director
Age: 61
Bio & Compensation  - Reuters
Raymond Wayne Cohen Independent Director
Age: 56
Bio & Compensation  - Reuters
Stuart M. Krassner Independent Director
Age: 79
Bio & Compensation  - Reuters
Luigi Lenaz M.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Anthony E. Maida III, Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters